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Abstract
Background: The term pseudohypoparathyroidism (PHP) describes disorders derived from resistance to the
parathyroid hormone. Albright hereditary osteodystrophy (AHO) is a disorder with several physical features that can
occur alone or in association with PHP.
The subtype 1B, classically associated with resistance to PTH and TSH, derives from the epigenetic dysregulation of
the GNAS locus. Patients showing features of AHO were described, but no explanation for such phenotypic
heterogeneity is available.
An AHO-like phenotype was associated with the loss of genetic information stored in chromosome 2q37, making
this genomic region an interesting object of study as it could contain modifier genes involved in the development
of AHO features in patients with GNAS imprinting defects.
The present study aimed to screen a series of 65 patients affected with GNAS imprinting defects, with or without
signs of AHO, for the presence of 2q37 deletions in order to find genes involved in the clinical variability.
Results: The molecular investigations performed on our cohort of patients with GNAS imprinting defects identified
two overlapping terminal deletions of the long arm of chromosome 2. The smaller deletion was of approximately 3
Mb and contained 38 genes, one or more of which is potentially involved in the clinical presentation. Patients with
the deletions were both affected by a combination of the most pathognomic AHO-like features, brachydactyly,
cognitive impairment and/or behavioural defects. Our results support the hypothesis that additional genetic factors
besides GNAS methylation defects are involved in the development of a complex phenotype in the subgroup of
patients showing signs of AHO.
Conclusions: For the first time, the present work describes PHP patients with hormone resistance and AHO signs
simultaneously affected by GNAS imprinting defects and 2q37 deletions. Although further studies are needed to
confirm the cause of these two rare molecular alterations and to identify candidate genes, this finding provides novel
interesting clues for the identification of factors involved in the still unexplained clinical variability observed in PHP1B.
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Background
The disorders related to parathyroid hormone (PTH) re-
sistance and PTH signalling pathway impairment are
historically named pseudohypoparathyroidism (PHP).
The term Albright hereditary osteodystrophy (AHO) de-
scribes a clinical entity that could also associate with
PHP, including several physical features such as brachy-
dactyly, subcutaneous ossifications, round face, short
stature, and obesity [1–3].
PHP is classified in different subtypes, PHP-1A,
pseudo-PHP, PHP-1B, PHP-1C and PHP-2, according to
the presence or absence of AHO, the in vivo response to
exogenous PTH and the in vitro activity of the α subunit
of the stimulatory G protein (Gsα), a key element of the
cAMP signalling pathway encoded by GNAS [1–4].
However, this classification fails to differentiate all the
patients due to the clinical and molecular overlap among
the PHP subtypes and the recent characterization of dis-
eases in the differential diagnosis of PHP. To clearly
identify each different subtype and create a classification
according to the molecular pathology, the EuroPHP net-
work established a new classification to cover all the dis-
orders of the PTH receptor and its signalling pathway,
proposing the name inactivating PTH/PTH-related pro-
tein signalling disorder (iPPSD) [5, 6]. In particular, the
iPPSD3 subtype includes methylation changes at one or
more GNAS differentially methylated regions (DMRs),
associated with or without a genetic (deletion) or cyto-
genetic (uniparental disomy (UPD)) defect.
Pseudohypoparathyroidism type 1B/iPPSD3 (MIM
#603233) patients classically show resistance to PTH
and TSH in the absence of additional clinical features,
but in the past years, patients showing physical features
of AHO have been described [7–12]. Several efforts were
made to find a correlation between the degree of GNAS
epigenetic defects and the severity of the disease in
terms of age at diagnosis (as a marker of disease preco-
city), the number or degree of hormonal resistances and
the number of AHO symptoms; however, no explanation
for the phenotypic heterogeneity in iPPSD3 was found
[11, 13, 14]. Among the factors that may explain the dif-
ferences in disease expression and deserve investigation
are modifier genes [15, 16].
Mutations in regions different from 20q were reported
in small subsets of clinically diagnosed PHP patients
with no detectable GNAS defects, highlighting the clin-
ical overlap with diseases in the differential diagnosis of
PHP: acrodysostosis (ACRDYS, PRKAR1A and PDE4D
genes, MIM#101800 and #614316, respectively) and bra-
chydactyly mental retardation syndrome (BDMR, also
known as AHO-like syndrome or 2q37 microdeletion
syndrome, MIM#600430) [5, 17].
From the molecular point of view, BDMR patients
carry structural rearrangements with breakpoints at or
within chromosome 2 region q37 [18]. Although BDMR
is a contiguous gene deletion syndrome with a signifi-
cantly variable clinical presentation, the hallmark re-
ported in almost all the patients is an AHO-like
phenotype characterized by mild to moderate intellec-
tual disability/developmental delay, behavioural abnor-
malities, short stature, obesity, a characteristically
dysmorphic face and brachydactyly type E [18].
The association of an AHO-like phenotype with the
loss of genetic information stored in the 2q37 makes this
genomic region interesting as it could contain modifier
genes involved in the development of AHO features in
iPPSD3 patients. Therefore, in the present study, we
screened 65 patients affected with broad sporadic GNAS
imprinting defects, with (n = 32) or without signs of
AHO (n = 33), for the presence of BDMR-associated
2q37 deletions in order to find genes possibly involved
in the phenotypic heterogeneity observed in iPPSD3.
Results
All the PHP patients were affected by sporadic GNAS
methylation alterations involving all the differentially
methylated regions (gain of methylation, GoM, at the
NESP DMR and loss of methylation, LoM, at the AS, XL
and AB DMRs) (Fig. 1). We excluded a 20q UPD in all
the cases.
The MLPA analysis identified two deletions that include
the 2q37 cytoband associated with BDMR. In particular,
the assay showed a 4.5Mb deletion from the COL6A3
gene to the PDCD1 gene in patient 4 and a 2.5Mb dele-
tion from the HDAC4 gene to the PDCD1 gene in patient
3 (Fig. 2a and Additional file 1: Table S2). Due to the limits
of the MLPA technique, point mutations and defects out-
side genomic sequences complementary to the MLPA
probes were not detected. We could not exclude the pres-
ence of genetic alterations different from CNVs in the
other patients. Molecular karyotyping is needed to pre-
cisely determine the extent of a deletion; thus, we per-
formed the array analysis for patient 4, and we confirmed
an 8.2Mb subtelomeric terminal 2q deletion,
46,XX;arr[hg19]2q37.1q37.3(234,782,915–243,029,273)x1
(Fig. 2b).
The qualitative and semiquantitative analysis of 2q37
VNTRs confirmed the rearrangements detected by MLPA
and allowed prediction of the extension of these genetic
defects with all the detected heterozygous VNTRs repre-
senting a biallelic condition (Additional file 2: Figure S1
and Additional file 1: Table S2). The semiquantitative PCR
analysis showed a signal reduction of approximately 50%
compared to that of the normal controls for the monoalle-
lic regions, reflecting the loss of the deleted allele.
Because both deletions were terminal, we were not
able to identify the precise upper breakpoint locations;
however, by merging the data obtained from different
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techniques, we determined the approximate size of
the defects and the number of deleted genes:
8,416,458–9,491,396 bps/55 genes for patient 4 and
2,924,948–3,893,174 bps/38 genes for patient 3 (Fig. 3
and Additional file 1: Table S2).
The smaller deletion detected in patient 3, which over-
lapped with that found in patient 4 and differs only in
the upper breakpoint, represented the smallest region of
overlap (SRO) containing the potential gene or genes in-
volved in the clinical presentation (Fig. 3 and Additional
file 1: Table S2).
Patient 4 presented resistance to PTH, brachydactyly,
psychomotor retardation, gastroesophageal and vesicour-
eteral reflux, celiac disease and subluxation of the tem-
poromandibular joint. The patient’s mother showed
signs of brachydactyly, which strengthens the idea of
inherited factors associated with specific clinical features.
Patient 3, in addition to resistance to PTH and TSH,
showed brachydactyly, neuro-psychomotor retardation
(IQ = 68–70%, need for extra help in school), stature
growth slowing (less than the 25th percentile), strabis-
mus and scoliosis.
According to the hypothesis of additional genetic factors
being involved in the development of a complex pheno-
type in the subgroup of iPPSD3 patients with signs of
AHO, both patients were affected by a combination of the
most pathognomic AHO-like features, which are
brachydactyly and cognitive impairment and/or behav-
ioural defects.
Discussion
The sporadic iPPSD3 is an imprinting disorder charac-
terized by methylation abnormalities at multiple GNAS
DMRs. Patients are resistant to the action of PTH and
TSH in the absence of additional clinical features, al-
though a subset of patients also presents physical fea-
tures of Albright hereditary osteodystrophy [8–12].
Several factors may underlie such differences in disease
expression including modifier genes. To date, no explan-
ation has been found for the apparent absence of
(epi)genotype-phenotype correlations, and the search for
possible causes is still underway [11, 12, 15, 16].
Recently, different research groups have reported mo-
lecular defects in regions different from 20q in small
subsets of clinically diagnosed PHP patients with no de-
tectable GNAS defects, further emphasizing the clinical
overlap with diseases in differential diagnosis such as the
BDMR [5, 17].
BDMR, initially called AHO-like syndrome, derives
from the loss of genes included in the 2q37 region; how-
ever, the large extension of known deletions has no
clearly defined candidate genes or established
genotype-phenotype correlations [18].
Fig. 1 Representative plots of the MS-MLPA analysis by Coffalyser showing the LoI at the GNAS locus in iPPSD3 patients. Left panel: copy number
analysis—data show a normal bialleleic status of the STX16 and GNAS regions, which means the absebce of any no structural defect (in particular
no deletions). Right panel: methylation analysis—data show a broad loss of imprinting at the GNAS locus. Calculated ratios are reported on the
Y-axis and probes on the X-axis. Red dots highlight the LoM (meth ratio < 0.5) and blue dots the GoM (meth ratio > 0.5)
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The experience gained in studying the molecular
mechanisms that explain the phenotypic heterogeneity
in iPPSD3 led us to hypothesize the involvement of
additional loci besides GNAS, and the best candidate
region for screening was the 2q37 region. Thus, we
investigated this genomic region in a cohort of 65
sporadic iPPSD3 patients (32 had signs of AHO and
33 did not) to determine the existence of a regulatory
and/or functional link between GNAS and the 2q37
region.
Fig. 2 a Plots of the MLPA analysis by Coffalyser showing the 2q37 deletions found in our cohort of iPPSD3 patients. Upper panel: patient 4, with
a deletion removing genes from COL6A3 to PDCD1. Lower panel: patient 3, with a deletion removing genes from HDAC4 to PDCD1. Calculated
ratios are reported on the Y-axis and probes on the X-axis. Red dots highlight the heterozygous deletion (allelic loss < 0.5). b Plot of the array
analysis performed in patient 4 confirming a 8.2 Mb subtelomeric terminal deletion of the long arm of the chromosome 2
(hg19 2:234,782,915—243,029,273)
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We found 2 different 2q37 deletions in 2 unrelated
subjects displaying signs of AHO that overlapped with
defects already associated with BDMR and included sev-
eral genes proposed to be responsible for the AHO-like
phenotype. Admittedly, limitations of this study were
that we could not perform the aCGH analysis for patient
3 to identify the precise size of the deletion and we did
not analyse parental samples to investigate the inherit-
ance and pathogenicity.
For appropriate genetic counselling, patients should be
made aware that 2q37 deletions are inheritable genetic
defects with a 50% recurrence risk in the offspring.
However, it is not currently possible to predict whether
such defects would associate with a clinical phenotype.
Several attempts to find a clear relationship between
phenotypic features and the minimal deletion interval
have been performed, but the clinical variability pre-
vented the obtaining of useful predictors of clinical pres-
entation [19, 20]. It must also be kept in mind that the
syndromic phenotype of 2q37 deletion patients might re-
sult from a contiguous gene deletion syndrome.
We selected potential candidate genes by localizing the
smallest region of overlap, which was a 3.8Mb sequence
containing 38 genes, and we compared it with 2q37 dele-
tions reported in the literature. This region, described by
Chassaing and Shrimpton (patient R.V.W.), is the smallest
region characterized in BDMR patients [21, 22]. The com-
mon clinical features reported in these two BDMR pa-
tients were an uneventful prenatal and birth history, a
normal hormone profile, delayed cognitive impairment/
moderate mental retardation, obesity, mild facial dys-
morphic features and brachydactyly. Our patients pre-
sented, in addition to the hormone resistance classically
associated with iPPSD3 and typically absent in BDMR,
brachydactyly and neuro-psychomotor impairment.
Moreover, similar to patient R.V.W., patient 3 also had
short stature and a dysmorphic face [21, 22].
According to their known function, HDAC4, PASK,
FARP2 and STK25 were confirmed as the most promising
candidate genes [21–25]. The histone deacetylase 4
(HDAC4, MIM*605314) is a corepressor for DNA-binding
transcription factors, playing a pivotal role in myogenesis,
skeletal development and neurogenesis [24, 25]. The PAS
kinase (PASK, MIM* 607505) is an evolutionarily con-
served protein that regulates the function of many intra-
cellular signalling pathways in response to both extrinsic
and intrinsic stimuli [23]. The FERM, ARHGEF, and
pleckstrin domain-containing protein 2 (FARP2, MIM*
617586) functions as a guanine nucleotide exchange factor
(GEF) for Rho family small GTPases and plays a role in
regulating the actin cytoskeleton [23]. The Serine/Threo-
nine protein kinase 25 (STK25, MIM* 602255) is a mem-
ber of the Ste20/PAK family implicated in heterotrimeric
G protein signalling [21, 22].
These data suggested that one or more genes essential
for skeletal morphogenesis and neurodevelopment were
located in the SRO. Such genes could encode proteins
acting through a Gsα-mediated transduction pathway
without affecting those activated by other mediators.
Both patients described in the present manuscript dis-
played signs of AHO in addition to the endocrine char-
acteristics of PTH resistance. Interestingly, hormone
resistance is usually absent in BDMR, although one pa-
tient with an AHO-like phenotype and raised levels of
PTH was described by Power and colleagues in 1997
[26]. No further comparison with the data from the lit-
erature could be performed since the BDMR patients
were not systematically evaluated for all the symptoms,
in particular for the endocrine function and the presence
of GNAS imprinting defects.
Fig. 3 Representative figure from the UCSC Genome Browser resuming the extension range of previously reported BDMR-associated deletions
and genes included. The smallest region of overlap (SRO) between known and our deletions is highlighted in red
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Imprinting disorders, such as transient neonatal diabetes
mellitus, have been associated with point mutations in
genes encoding factors involved in the establishment and/
or maintenance of imprinting [27, 28]. It is unclear
whether imprinting defects causing the sporadic form of
iPPSD3 are secondary to the genetic defects. Due to the
large extension of the 2q37 deletion and the high content
in transcripts with an unknown function, this region could
host genes involved in GNAS epigenetic regulation and
should be considered in future studies.
In conclusion, we first described the existence of
iPPSD3 patients with hormone resistance and AHO
signs simultaneously affected by GNAS imprinting de-
fects and 2q37 deletions. The discovery of these complex
genotypes highlighted the difficulty in the interpretation
of genetic testing in the presence of a combination of
rare molecular alterations in the same individual. The
screening of 2q37 deletions is already indicated in the
molecular diagnostic setting of patients who show sev-
eral features of AHO but have normal Gsα levels and no
endocrine abnormalities. In our opinion, it is premature
to propose the search for 2q37 alterations in patients
with iPPSD3 for diagnostic purposes since only two af-
fected patients have been identified so far. Further stud-
ies to confirm a causality between GNAS and 2q37
defects and to identify novel candidate genes are needed.
Nevertheless, considering approximately 20% of patients
with GNAS epigenetic defects have hormone resistance
with AHO signs [29], our findings provide interesting
clues for the identification of factors involved in the still
unexplained clinical variability observed in iPPSD3.
Materials and methods
The study included 65 patients with a clinical diagnosis
of a sporadic iPPSD3. Most patients have been reported
in our previous work to investigate the presence of a
correlation between GNAS epigenetic alterations and
clinical characteristics in patients with pseudohypopar-
athyroidism type 1 [30].
The clinical diagnosis of PHP was based upon the pres-
ence of PTH resistance, i.e., hypocalcaemia, hyperpho-
sphatemia and raised serum PTH levels in the absence of
vitamin D deficiency and renal insufficiency. Twenty-five
out of the 65 patients presented with TSH resistance, doc-
umented by raised TSH serum levels (TSH > 3.9mU/L) in
the absence of anti-thyroid antibodies and the presence of
a normal thyroid scan (data not shown).
Thirty-two patients showed at least 1 and up to 4 typical
AHO manifestations, which include brachydactyly (n = 13,
shortening of the fourth and/or fifth metacarpals defined
as the metacarpal sign and/or shortening below − 2SDS at
the metacarpophalangeal profile pattern in at least one
metacarpal bone or distal phalanx), short stature (n = 10,
height below the 3rd percentile for chronological age),
obesity (n = 15, BMI > 30 kg/m2 in adults and weight >
97th percentile in children), round face (n = 17), and cog-
nitive impairment and/or behavioural defects (n= 9). Only
two subjects of this group showed both brachydactyly and
mental/behavioural defects, which are clinical manifesta-
tions associated with BDMR.
The clinical details are shown in Additional file 1: Table
S1. Informed consent for genetic and epigenetic studies
was obtained from all the subjects involved in the study.
The molecular investigations were performed on the gen-
omic DNA extracted from peripheral blood (Nucleon
BACC2 genomic DNA purification kit, GE Healthcare, Pis-
cataway, NJ, USA). The direct sequencing of GNAS coding
exons and flanking intronic sequences (ENSEMBL ID:
ENSG00000087460) and the methylation-specific-multiplex
ligand-dependent probe amplification (MS-MLPA, ME031
vB1-1012 GNAS probemix by MRC-Holland, Amsterdam,
The Netherlands) analysis were performed as previously de-
scribed [30, 31].
Informative genetic markers, such as variable number
tandem repeats (VNTRs) in the 20q region, were evalu-
ated by capillary electrophoresis of fluorescent-labelled
PCR amplicons (ABI3130xl Genetic Analyzer, Applied
Biosystems, Foster City, CA) to exclude the presence of
uniparental disomy (UPD) [32].
The presence of copy number variants (CNVs) affect-
ing the 2q37 region was detected by MLPA using the
P264-Human Telomere-9 vB1-0514 (MRC-Holland,
Amsterdam, The Netherlands). The data analysis was
carried out using the Coffalyser software (MRC-Holland,
Amsterdam, The Netherlands).
For the 2q37 VNTRs genotyping (for a complete list
of tested VNTRs see the Additional file 1: Table S2), we
set up a cost-effective three-primer approach based on
the simultaneous use of a couple of sequence-specific
primers, where the reverse primer containing a poly-A
tail at the 5′ end to allow easier allele scoring, associated
with a fluorescently labelled universal forward M13 tail
FAM oligonucleotide. All primers and experimental con-
ditions are available upon request.
Additionally, in 1 patient bearing the 2q37 deletion, a
genome-wide genotyping array was performed using the
HumanCytoSNP-12 (Illumina, San Diego, California,
USA). A panel designed for the analysis of genetic and
structural variations that are most relevant to human
disease and data analysis was performed with the Blue-
Fuse Multi Software v4.4.
Additional files
Additional file 1: Table S1. Clinical characteristics and molecular
analysis of patients included in the present study. Abbreviations and
symbols: ID, identification number; F, female; M, male; ↑, value not
available but reported as above reference range; ↔, value not available
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but reported as in range; ↓, value not available but reported as below
reference range; SS, short stature; Ob, obesity; RF, round/dysmorfic facies;
Br, brachydactyly; MR, mental retardation and/or behavioural defects; OS,
ectopic ossification. The molecular diagnosis age is reported in years.
Biochemical values outside the normal range are highlighted in bold. For
PTH, the normal range is 10–65 pm/mL; for TSH, the normal range is
0.4–3.9 mU/L; for calcemia, the normal range is 9.0–10.5 mg/dL; for
phoshpatemia, the normal range is 2.8–4.5 mg/dL. Table S2. Table
resuming analysed variable number tandem repeats (VNTR), MLPA probes
and gene location in the 2q37 region of deleted patients. Abbreviations:
het, heterozygous; homo, homozygous; del, deleted. (DOCX 47 kb)
Additional file 2: Figure S1. 2q37 marker analysis in iPPSD3 deleted
patients for confirm and characterize found structural rearrangements.
Selection of homozygous (1 peak) and heterozygous (2 peaks) VNTRs
from patients 3 (right panels) and 4 (left panels). (PPTX 4081 kb)
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BDMR: Brachydactyly mental retardation syndrome; DMR: Differentially
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